MA71282A1 - Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine - Google Patents

Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine

Info

Publication number
MA71282A1
MA71282A1 MA71282A MA71282A MA71282A1 MA 71282 A1 MA71282 A1 MA 71282A1 MA 71282 A MA71282 A MA 71282A MA 71282 A MA71282 A MA 71282A MA 71282 A1 MA71282 A1 MA 71282A1
Authority
MA
Morocco
Prior art keywords
enavogliflozin
prevention
treatment
pharmaceutical composition
nephropathy
Prior art date
Application number
MA71282A
Other languages
English (en)
Inventor
Hye Young JI
Hwa Rang SONG
Young Hee Kim
Jae Jin NAH
Wan Huh
Seung Ah Cho
Mi Hee Park
Si Eun Lee
Su Young Kim
Bo Young Cho
Jae Min Cho
Seong In Cho
Ji-Soo Choi
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of MA71282A1 publication Critical patent/MA71282A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant de l'énavogliflozine en tant que principe actif pour la prévention ou le traitement du diabète et/ou de néphropathies chez des patients qui ont ou risquent de contracter des diabète et/ou des néphropathies.
MA71282A 2022-10-05 2023-10-05 Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine MA71282A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220127340 2022-10-05
PCT/KR2023/015349 WO2024076177A1 (fr) 2022-10-05 2023-10-05 Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine

Publications (1)

Publication Number Publication Date
MA71282A1 true MA71282A1 (fr) 2025-12-31

Family

ID=90608375

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71282A MA71282A1 (fr) 2022-10-05 2023-10-05 Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine

Country Status (10)

Country Link
EP (1) EP4599828A1 (fr)
JP (1) JP2025533903A (fr)
KR (1) KR20240047952A (fr)
CN (1) CN119997945A (fr)
AU (1) AU2023355275A1 (fr)
CL (1) CL2025001006A1 (fr)
MA (1) MA71282A1 (fr)
MX (1) MX2025004001A (fr)
WO (1) WO2024076177A1 (fr)
ZA (1) ZA202502846B (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160043519A (ko) * 2014-10-13 2016-04-21 주식회사 엘지생명과학 제미글립틴 및 제미글립틴 활성 대사체를 이용한 혈관 합병증의 예방 및 치료
WO2021207723A2 (fr) * 2020-04-10 2021-10-14 Chinook Therapeutics, Inc. Méthodes de traitement d'une maladie rénale diabétique
US20210353593A1 (en) * 2019-12-17 2021-11-18 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with atrasentan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002425A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EA201300522A1 (ru) * 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
US9034921B2 (en) 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
KR20150130177A (ko) * 2014-05-13 2015-11-23 한미약품 주식회사 Sglt 저해제로서 2,3-다이하이드로벤조퓨란 유도체 및 이를 포함하는 약학적 조성물
TN2018000437A1 (en) 2016-06-17 2020-06-15 Dae Woong Pharma Method for producing diphenylmethane derivative
KR102573466B1 (ko) 2020-01-29 2023-09-01 아틀라스 콥코 인더스트리얼 테크니크 에이비 토크가 펄스로 전달되는 조임 공정을 수행하도록 구성된 전기 공구

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160043519A (ko) * 2014-10-13 2016-04-21 주식회사 엘지생명과학 제미글립틴 및 제미글립틴 활성 대사체를 이용한 혈관 합병증의 예방 및 치료
US20210353593A1 (en) * 2019-12-17 2021-11-18 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with atrasentan
WO2021207723A2 (fr) * 2020-04-10 2021-10-14 Chinook Therapeutics, Inc. Méthodes de traitement d'une maladie rénale diabétique

Also Published As

Publication number Publication date
MX2025004001A (es) 2025-05-02
ZA202502846B (en) 2025-12-17
JP2025533903A (ja) 2025-10-09
WO2024076177A1 (fr) 2024-04-11
AU2023355275A1 (en) 2025-04-24
KR20240047952A (ko) 2024-04-12
CN119997945A (zh) 2025-05-13
CL2025001006A1 (es) 2025-05-30
EP4599828A1 (fr) 2025-08-13

Similar Documents

Publication Publication Date Title
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
Lee et al. PGC1α activators mitigate diabetic tubulopathy by improving mitochondrial dynamics and quality control
US10314914B2 (en) Iodophor composition and methods of use
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
Jeong et al. Chloroquine and amodiaquine enhance AMPK phosphorylation and improve mitochondrial fragmentation in diabetic tubulopathy
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA29227B1 (fr) 4-phenyltetrahydroisoquinoline substituees, leur procedes de fabrication, leur utilisation en tant que medicament et medicament les contenant
MA56607A1 (fr) Méthodes de traitement de troubles dépressifs
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA58093B1 (fr) Nouveaux analogues d'insuline et leurs utilisations
MA71282A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une néphropathie et/ou du diabète sucré, comprenant de l'énavogliflozine
FR2393577A1 (fr) Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse
Garcia et al. Inactivation of adenovirus in water by natural and synthetic compounds
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
EP4501918A4 (fr) Dérivé de 3-phénylisoxazole et composition pharmaceutique pour prévenir ou traiter une maladie oculaire le contenant en tant que principe actif
MA30662B1 (fr) Derives de phenyl-prenyl-ether pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
MA50979B1 (fr) Application de totarol et composition pharmaceutique contenant du totarol
MA53521B1 (fr) Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
MA57215B1 (fr) Composés comprenant un nitrile comme antiviraux pour le traitement d'une infection à coronavirus
MA58511B1 (fr) Azélastine en tant que traitement antiviral
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag